In this multicenter randomized controlled trial of nonbleeding patients with INR levels between 4.5-10, they were randomized to placebo or vitamin K 1.25mg orally. At 90 days, there was no difference between the groups in bleeding (each 16%), or thromboembolism (1%), although the INR did decrease faster in the vitamin K group (1.4 in placebo versus 2.8 in vitmain K, in the 1st day) (abstract). This is fairly consistent with the current ACCP guidelines, which suggest omitting 1-2 doses of warfarin for INR levels 5-9 (with vitamin K reserved for patients at high risk of bleeding) (guidelines).
Share This Post
Categories
Related Posts
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]
Leave A Comment